



NSW
Therapeutic
Advisory
Group Inc.

Advancing
quality use
of medicines
in NSW

TAG Mail

14 September 2023

A fortnightly newsletter for quality use of medicine healthcare practitioners

NSW TAG ACTIVITIES

Thank you to members who provided feedback regarding TGA Review of Medicines Labelling Rules and CATAG enquiry regarding re-purposing of medicines. Discussion of responses will occur at the NSW TAG General meeting 19th October.

Upcoming TAG meeting dates

NSW TAG General Meeting 19th October 3-4.30pm
NSW Annual General Meeting 19th October 4.30pm

Upcoming CATAG meetings

CATAG Members meeting 25th October 2023

OTHER NEWS

NSW Health

- Opioid Treatment Program - Transition to Section 100 Highly Specialised Drugs Program - [link](#)

TGA

- Changes to choline salicylate access to start from 1 October 2023 - [link](#)

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)

The latest weekly Evidence Digests can be found [here](#)

Australian Institute for Health and Welfare (AIHW)

- Australia's welfare 2023 - [link](#)
- Rural and remote health - [link](#)
- Health of young people - [link](#)
- Health of children - [link](#)
- Burden of avoidable deaths among Aboriginal and Torres Strait Islander people 2018 - [link](#)

MIMS monthly updates, [September 2023](#)

- New indications
- Dapagliflozin (propanediol monohydrate) ([Forxiga](#)) – adult symptomatic heart failure independent of left ventricular ejection fraction, as an adjunct to standard of care therapy
- Dupilumab ([Dupixent](#)) - severe atopic dermatitis in patients aged 6 months to 11 years old who are candidates for chronic systemic therapy
- Ferric carboxymaltose ([Ferinject](#)) - iron deficiency anaemia in children aged 1 to 13 years when oral iron preparations are ineffective or cannot be used
- Finerenone ([Kerendia](#)) - to reduce the risk of adult cardiovascular mortality and morbidity in chronic kidney disease (with albuminuria) associated with Type 2 diabetes, in addition to standard of care
- Influenza virus vaccine, surface antigen, quadrivalent (inactivated) ([Flucelvax](#) Quad) - children from 6 months of age and older to help prevent influenza virus types A and B

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Upadacitinib ([Rinvog](#)) - moderate to severe active adult Crohn's disease, who have had inadequate response, lost response or were intolerant to either conventional therapy or a biological medicine
- Sacituzumab govitecan ([Trodelvy](#)) – adults with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy (including a CDK4/6 inhibitor) and at least two additional systemic therapies in the locally advanced or metastatic setting

PBS

- Information regarding brands availability of colestyramine with changes to PBS listing of s19A JAMP CHOLESTYRAMINE effective 1 September 2023 - [link](#)

TGA

- [Database](#) of section 19A approvals to import and supply medicines to address medicine shortages
- [Bendarabine](#) fludarabine 50mg powder for injection or infusion (Germany) - until 30/04/
- [Ampicillin](#) for injection, USP 1g/vial (Mylan, USA) - until 30/11/2023
- AusPARs:
 - [Gardasil 9](#) (HPV 9-valent vaccine, recombinant) – extension of indications - prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions, infection caused by HPV in males
 - [Spikevax](#) Bivalent Original/Omicron BA.4 - 5 (Elasomeran/davesomeran) – full registration for the prevention of coronavirus disease 2019 caused by SARS-CoV-2
 - [Vaxneuvance](#) (Pneumococcal 15-valent conjugate vaccine (CRM197 protein), adsorbed) for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes
 - [Comirnaty](#) (tozinameran) – dose change – for prevention of coronavirus disease 2019 (COVID-19)
 - [Vazkepa](#) (icosapent ethyl) to reduce the risk of cardiovascular events
- Australian prescription medicine decision summaries:
 - [Xenpozyme](#) (olipudase alfa) - non-central nervous system (CNS) manifestations of acid sphingomyelinase deficiency (ASMD)

REPORTS AND PUBLICATIONS – INTERNATIONAL

Academic Health Science Network (ASHN)

- Polypharmacy Programme Interim Evaluation: Executive Summary and Year 1 Impact - [link](#)

Department of Health and Social Care UK

- Nitrous oxide: legitimate uses and appropriate controls - [link](#)

electronic Medicines Compendium (eMC) (UK)

- [New products](#)
 - Aquipta (atogepant) 10 and 30 mg tablets - CGRP receptor antagonist licensed for migraine prophylaxis in adults who have at least 4 migraine days per month. Dose is 60 mg once daily, which should be reduced to 10mg once daily if there is concomitant use of strong CYP3A4 inhibitors or strong OATP inhibitors
 - Combogesic IV 10 mg/ml + 3 mg/ml [1000mg / 300mg in 100ml] solution for infusion (paracetamol / ibuprofen) licensed for use in adults for the short-term symptomatic treatment of acute moderate pain and the reduction of fever, where an IV route of administration is considered clinically necessary and/or when other routes of administration are not possible
 - Gadobutrol 1.0 mmol/mL solution for injection in pre-filled syringe licensed for contrast enhancement in cranial, spinal, liver, kidneys, angiography MRI, and whole body pathologies
 - Macimorelin 60 mg granules for oral suspension in sachet, a peptidomimetic with growth hormone (GH) secretagogue activity licensed for adult GH deficiency
 - Ceyesto (melatonin) 1mg/ml Oral Solution - licensed for: delayed sleep wake phase disorder in patients age 6-25 years, short-term treatment of jet lag in adults, insomnia in patients age 6-17 years with ADHD, and as single dose for sedation for electroencephalograms in patients age 1-18 years

- Comirnaty (raxtozinameran) Omicron XBB.1.5 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified) licensed for active SARS-CoV-2 COVID-19 immunisation in individuals in various age groups
- Byfavo (remimazolam) 50 mg powder for concentrate solution for injection/infusion - new formulation, an ultra-short acting benzodiazepine sedative/hypnotic, licensed for intravenous induction and maintenance of general anaesthesia in adults

Food and Drug Administration (FDA) USA

- New Drug approvals
- [Aphexda](#) (motixafortide) - with filgrastim (G-CSF) to mobilize hematopoietic stem cells to peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma
- Applications
- [dabrafenib](#) (Tafinlar) - for BRAF V600E-positive solid tumors expanded to include children aged 1 year and older
- [trametinib](#) (Mekinist) - indication expanded to children aged 1 year and older for BRAF V600E-positive solid tumors
- [canakinumab](#) (Ilaris) - new indication approved for treatment of gout flares

Medicines and Healthcare products Regulatory Agency (MHRA)

- Guidance published on the new international regulatory recognition routes for medicines approvals - [link](#)

MIMS, UK

- New twice-weekly rivastigmine patch for Alzheimer's disease - [link](#)

NHS England

- Addressing palliative and end of life care needs for people living with heart failure: a revised framework for integrated care systems - [link](#)

National Institute for Health and Clinical Excellence (NICE) UK

- NICE committee recommends [tirzepatide](#) as new treatment option for people with type 2 diabetes
- Semaglutide for managing overweight and obesity, updated ([TA875](#)) – [SPS Commentary](#)
- Caesarean birth – guidance ([NG192](#)) – update
- Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy ([TA913](#))
- Spinal metastases and metastatic spinal cord compression ([NG234](#)) – [SPS commentary](#)
- Cirrhosis in over 16s: assessment and management, updated ([NG50](#))
- Final draft guidance
- Bimekizumab for treating active psoriatic arthritis [[ID4009](#)]
- Bimekizumab for treating axial spondyloarthritis [[ID6245](#)]
- Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments [[ID3970](#)]

Pharma

- Retinopathy of prematurity (ROP) and EYLEA® ([aflibercept](#)): Information for parents and caregivers

Scottish Intercollegiate Guideline Network (SIGN) UK

- [SIGN146](#): Cutaneous melanoma

Scottish Medicines Consortium

- Accepted for use in NHS Scotland
- [daratumumab](#) (Darzalex) with lenalidomide and dexamethasone for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant
- [ibrutinib](#) (Imbruvica) with venetoclax for the treatment of adults with previously untreated chronic lymphocytic leukaemia
- [Vutrisiran](#) (Amvuttra), double-stranded small interfering ribonucleic acid (siRNA) for use in hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adults with stage 1 or stage 2 polyneuropathy

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Accepted for restricted use: [Rimegepant](#) (Vyndura®) for episodic migraine prevention in adults who have ≥4 migraine attacks per month, but <15 headache days per month and who have had prior failure on ≤3 migraine preventive treatments
- Not accepted for use: [mosunetuzumab](#) (Lunsumio) as monotherapy for the treatment of adults with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies
- Completes initial assessment of the evidence for eladocogene exuparvovec (Upstaza) for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency with a severe phenotype – [link](#) and [SPS commentary](#)
- Completes initial assessment of the evidence for olipudase alfa (Xenpozyme) for the treatment of non-Central Nervous System manifestations of Acid Sphingomyelinase Deficiency (ASMD) – [link](#) and [SPS commentary](#)

UK Health Security Agency

- National protocol for COVID-19 vaccine (adults) – [update](#) and [SPS commentary](#)

World Health Organisation (WHO) - World Patient Safety Day - 17 September 2023

- WHO Special Initiative for Mental Health - [link](#)
- WHO's operational handbook on tuberculosis infection prevention and control - [link](#)

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)

- [Revised SPCs](#)
- Benadryl (cetirizine dihydrochloride) - drug-induced liver injury and other types of non-infectious hepatitis possible adverse reactions (frequency not known)
- Bimzelx (bimekizumab) - new indication of adult psoriatic arthritis with inadequate response /intolerance to ≥1 DMARDs. Treatment should be stopped in the case of infection that becomes serious /unresponsive to standard therapy
- Vocabria (cabotegravir) – data added from retrospective analysis of 3 studies in 29 subjects who received oral bridging for median duration of 59 days with ART other than Vocabria plus rilpivirine (alternative oral bridging) during treatment with Vocabria plus rilpivirine LA IM injections
- Ruconest (conestat alfa) - serious arterial and venous thromboembolic events have been reported at recommended dose of plasma derived C1 esterase inhibitor products in patients with known risk factors: monitor these patients closely
- Comirnaty (COVID-19 mRNA Vaccine) - updated to state individuals may not be fully protected until 7 days after their vaccination, new posology for primary immunisation; lymphadenopathy now a common adverse effect; shelf life extended from 18 months to 2 years
- Lixiana (edoxaban) - clarithromycin (500 mg twice daily) for 10 days with a single concomitant dose of edoxaban 60mg on day 9 increased the edoxaban AUC and Cmax by approximately 53% and 27%, respectively. Anticoagulant-related neuropathy added as an ADR.
- Ergometrine Injection - can be stored outside of the refrigerator at a temperature of up to 25°C for a maximum 12 weeks, after which it should be discarded. (Do not place back into refrigerator, once it has been kept outside)
- Yasmin (ethinylestradiol, drospirenone) - ALT elevations reported when used with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin and glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir. Now contraindicated with concomitant use of sofosbuvir/velpatasvir/voxilaprevir
- Nurofen (ibuprofen) - renal tubular acidosis and hypokalaemia may occur following acute overdose and use over long periods at high doses; from the 20th week of pregnancy, ibuprofen use may cause oligohydramnios resulting from foetal renal dysfunction
- Oruvail (ketoprofen) - increased risk for arterial thrombotic events reported in patients on non-aspirin NSAIDs (e.g. parecoxib & valdecoxib) for perioperative pain in setting of coronary artery bypass surgery has not been observed with ketoprofen
- Lenvima and Kisplyx (lenvatinib) - details added on preparing and administering a suspension from the hard capsules

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Camzyos (mavacamten) - selective, allosteric, and reversible cardiac myosin inhibitor for symptomatic (NYHA, class II-III) obstructive adult hypertrophic cardiomyopathy
- Hypnovel (midazolam) - Kounis syndrome (cardiovascular symptoms secondary to allergic or hypersensitivity insults) added as a potential ADR (frequency unknown)
- Rydapt - 'acute febrile neutrophilic dermatosis' included as an ADR (frequency not known).
- Losec (omeprazole) - no or negligible influence on the ability to drive and use machines. However, if ADRs such as dizziness and visual disturbances occur, patients should not drive or use machines
- Pemazyre (pemigatinib) - cutaneous calcification as a possible uncommon ADR.
- Gavreto (pralsetinib) - TB, mostly extrapulmonary, reported as an uncommon ADR. Antimycobacterial therapy needs to be started in those with active/latent TB before Gavreto initiation
- Ropivacaine hydrochloride - Horner's syndrome (a condition that results from an interruption of the sympathetic nerve supply to the eye) added as .ADR
- Buccastem (prochlorperazine) - updated to note it may potentiate QT interval prolongation which increases the risk of serious ventricular arrhythmias. Use with caution in patients with, or have risk factors for, QT prolongation
- Adynovi (rurioctocog alfa pegol) - anaphylaxis added as ADR (frequency unknown)
- Retsevmo (selpercatinib) - hypothyroidism reported. Also, can inhibit D2 deiodinase & thereby decrease conversion of levothyroxine (T4) to liothyronine (T3) so patients may have insufficient response to T4 and may require supplementation with T3
- Risk minimisation materials
- Camzyos (mavacamten) – HP checklist for HP including embryo-foetal toxicity risks, heart failure due to systolic dysfunction, and adverse events due to overexposure (drug interactions)

EMA

- PRAC recommends new measures to avoid topiramate exposure in pregnancy - [link](#)

Health Canada – MedEffect Notice

- Health Product InfoWatch: [August 2023](#)
- Domperidone and psychiatric withdrawal events when used off-label for lactation stimulation
- Medication errors with specific mineral supplements: calcium, iron, magnesium, and zinc

Institute for Safe Medication Practices (ISMP) USA

- Medication Safety Alert! [September 7, 2023](#)
- Drug, Supply, and Equipment Shortages Continue to Compromise Patient Care – [link](#)
- Limitations of the most recent posaconazole formulation
- Confusing FLUZONE high-dose packaging

Medsafe (New Zealand Medicines and Medical Devices Safety Authority)

- Prescriber Update 44(3) [September 2023](#) includes
- Spotlight on clonidine - [link](#)
- Reports of persisting serious adverse reactions to fluoroquinolones - [link](#)
- Antidepressant withdrawal: taper antidepressants slowly - [link](#)
- Recent data sheet updates: important new safety information - [link](#)
- Vanishing bile duct syndrome – a complication of drug-induced liver injury - [link](#)
- Infusion-related reactions – not all allergy related - [link](#)

MIMS monthly updates

- New Contraindications
- Ravulizumab ([Ultomiris](#) 100 mg/mL) - in patients who are not currently vaccinated against Neisseria meningitidis, unless they receive prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination

Specialist Pharmacy Services NHS UK

- Managing pharmaceutical waste - [link](#) and [SPS commentary](#)
- Considerations when switching between solid doses and liquids – [link](#) and [SPS commentary](#)
- Specific medicine switches for solid dose and liquid formulations – [link](#) and [SPS commentary](#)

PAPERS OF INTEREST

American Journal of Cardiology

- CYP2C19 Genotype Prevalence and Association With Recurrent Myocardial Infarction in British–South Asians Treated With Clopidogrel - [link](#)
- Angiotensin Receptor–Neprilysin Inhibitor Effects on Atherosclerotic Cardiovascular Disease Events: A Meta-Analysis of Randomized Controlled Trials - [link](#)
- Effect of furosemide versus torsemide on hospitalizations and mortality in patients with heart failure: a meta-analysis of randomized controlled trials - [link](#)

American Journal of Gastroenterology

- Systematic Review With Meta-Analysis: Chronic Opioid Use Is Associated With Esophageal Dysmotility in Symptomatic Patients - [link](#)

American Journal of Health-System Pharmacy (AJHP)

- Implementation of a pharmacy-driven rapid bacteremia response program - [link](#)
- The Pharmacy 5.0 framework: A new paradigm to accelerate innovation for large-scale personalized pharmacy care - [link](#)
- Nirsevimab-alip - [link](#)
- Infectious complications among patients receiving ibrutinib for the treatment of hematological malignancies - [link](#)
- Cold chain management in health systems: Navigating a complex and evolving landscape - [link](#)
- Administration of andexanet alfa for traumatic intracranial hemorrhage in the setting of massive apixaban overdose: A case report - [link](#)
- An interrupted time series study of electronic health record clinical decision support for providers caring for patients with atrial fibrillation at increased stroke risk - [link](#)

American Journal of Kidney Disease

- Vitamin D Therapy in Adults With CKD: A Systematic Review and Meta-analysis – [link](#) - [commentary](#)

Annals of Internal Medicine

- Comparative Safety Analysis of Oral Antipsychotics for In-Hospital Adverse Clinical Events in Older Adults After Major Surgery: A Nationwide Cohort Study - [link](#)
- In the clinic: Travel Medicine - [link](#)

Annals of Rheumatic Diseases

- Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial – [link](#) – [SPS commentary](#)

Arthritis & Rheumatology

- Long-term efficacy/safety of canakinumab in patients with tumor necrosis factor receptor-associated periodic syndrome: results from a phase III trial - [link](#)

Australian Health Review, Journal of the Australian Healthcare & Hospitals Association

- Emerging health and social policy considerations for safe and quality end-of-life care in Australia – the evidence, gaps and challenges - [link](#)

British Journal of Clinical Pharmacology

- Evaluating the performance of ChatGPT in clinical pharmacy: A comparative study of ChatGPT and clinical pharmacists - [link](#)
- ChatGPT in pharmacometrics? Potential opportunities and limitations - [link](#)
- Considerations on implementation of the newest treatment for symptomatic uterine fibroids: oral GnRH antagonists - [link](#)
- Implementation of a clinical decision support system for the optimization of antidiabetic drug orders by pharmacists - [link](#)

- Review: Paracetamol (acetaminophen) poisoning: The early years – [link](#) – [SPS commentary](#)
- Tools and guidelines to assess the appropriateness of medication and aid the deprescribing: an umbrella review - [link](#)
- Letter: Meloxicam-induced capillaritis with positive rechallenge - [link](#)
- Key factors associated with 6-thioguanine and 6-methylmercaptapurine nucleotide concentrations in children treated by thiopurine for acute leukaemia and inflammatory bowel disease - [link](#)
- Continuous infusion of cefiderocol in a critically ill patient with continuous venovenous haemofiltration - [link](#)
- A case of acute pulmonary complication due to botulinum toxin: Patient with central pontine myelinolysis developed acute respiratory distress syndrome after botulinum neurotoxin type A injection into spastic lower extremity muscles - [link](#)

British Journal of General Practice

- Adherence to 5-aminosalicylic acid maintenance treatment in young people with ulcerative colitis: a retrospective cohort study in primary care - [link](#)
- Pre-diagnostic prescription patterns in bladder and renal cancer: a longitudinal linked data study - [link](#)

British Journal of Psychiatry

- Drug-related deaths among housed and homeless individuals in the UK and the USA: comparative retrospective cohort study - [link](#)

British Medical Journal (BMJ)

- Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies - [link](#)
- Two-drug antiretroviral regimens for HIV - [link](#)
- Personality disorder - [link](#)
- Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial - [link](#)
- Essential medicines lists are for high income countries too - [link](#)
- Pyoderma gangrenosum - [link](#)
- Food additive emulsifiers and risk of cardiovascular disease in the NutriNet-Santé cohort: prospective cohort study - [link](#)
- Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs: nationwide cohort study – [link](#) – [SPS commentary](#)
- Management of epilepsy during pregnancy and lactation - [link](#)
- Prevent TB to end TB - [link](#)
- Glucose monitoring and glucose lowering agents for children and young people with type 2 diabetes: summary of updated NICE guidance – [link](#) - [SPS commentary](#)

BMC Medicine

- Healthcare fragmentation, multimorbidity, potentially inappropriate medication, and mortality: a Danish nationwide cohort study - [link](#)

BMJ Open

- Safety of influenza vaccination during pregnancy: a systematic review - [link](#)

Circulation

- Associations of Apixaban Dose With Safety and Effectiveness Outcomes in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease – [link](#) – [SPS commentary](#)

Cochrane

- Platinum-based chemotherapy for early triple-negative breast cancer - [link](#)

Diabetes Care

- Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes - [link](#)

Diabetes, Obesity and Metabolism

- Cardiovascular efficacy and safety of antidiabetic agents: A network meta-analysis of randomized controlled trials – [link](#) – [SPS commentary](#)

Drug and Therapeutics Bulletin

- Managing drugs with anticholinergic activity - [link](#)

Emergency Medicine Journal

- Comparison of intravenous paracetamol (acetaminophen) to intravenously or intramuscularly administered non-steroidal anti-inflammatory drugs (NSAIDs) or opioids for patients presenting with moderate to severe acute pain conditions to the ED: systematic review and meta-analysis – [link](#) - [commentary](#)

European Heart Journal

- 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria - [link](#) – [SPS commentary](#)
- Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial - [link](#)
- Beta-blockers in non-obstructive hypertrophic cardiomyopathy: time to ease the heart rate restriction? - [link](#)
- Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction - [link](#)

European Journal of Hospital Pharmacy

- Do junior doctors make more prescribing errors than experienced doctors when prescribing electronically using a computerised physician order entry system combined with a clinical decision support system? A cross-sectional study - [link](#)
- European Association of Hospital Pharmacists (EAHP) position paper: Digital health - [link](#)
- European Association of Hospital Pharmacists (EAHP) position paper: Infectious diseases and antimicrobial resistance - [link](#)

Heart

- Optimal antiplatelet strategy following coronary artery bypass grafting: a meta-analysis - [link](#)
- Beta-blockers and renin-angiotensin system inhibitors for Takotsubo syndrome recurrence: a network meta-analysis – [link](#) – [SPS commentary](#)

Internal Medicine Journal

- Provision of continuous subcutaneous insulin infusion to type 1 diabetes 'frequent flyers' - [link](#)

International Journal of Clinical Pharmacy

- Look-alike medications in the perioperative setting: scoping review of medication incidents and risk reduction interventions - [link](#)
- Prevalence, contributing factors, and interventions to reduce medication errors in outpatient and ambulatory settings: a systematic review - [link](#)
- Development and partial validation of Be-CLIPSS: a classification system for hospital clinical pharmacy activities - [link](#)

JAMA

- Blood Pressure Management After Endovascular Therapy for Acute Ischemic Stroke: The BEST-II Randomized Clinical Trial – [link](#) – [SPS commentary](#)
- Intensive vs Conventional Blood Pressure Lowering After Endovascular Thrombectomy in Acute Ischemic Stroke: The OPTIMAL-BP Randomized Clinical Trial – [link](#) – [SPS commentary](#)
- Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL-ACS Data – [link](#) – [SPS commentary](#)
- Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial - [link](#)

- Efficacy and tolerability of gefapixant for treatment of refractory or unexplained chronic cough: A Systematic Review and Dose-Response Meta-Analysis – [link](#) – [SPS commentary](#)
- Ulcerative Colitis in Adults: A Review - [link](#)

JAMA Cardiology

- Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial – [link](#) – [SPS commentary](#)

JAMA Dermatology

- Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment: A Systematic Review and Meta-Analysis - [link](#)

JAMA Internal Medicine

- Estimated Lifetime Gained With Cancer Screening Tests: A Meta-Analysis of Randomized Clinical Trials – [link](#) – [SPS commentary](#)

JAMA Neurology

- Vaccines and the Risk of Hospitalization for Multiple Sclerosis Flare-Ups - [link](#)
- Efficacy and safety of ravulizumab, a complement C5 inhibitor, in adults with amyotrophic lateral sclerosis - [link](#)

JAMA Oncology

- Use of Artificial Intelligence Chatbots for Cancer Treatment Information – [link](#) – [SPS commentary](#)
- Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis - [link](#)
- Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs? - [link](#)
- Neoadjuvant Immune Checkpoint Inhibitor Therapy for Localized Deficient Mismatch Repair Colorectal Cancer (dMMR CRC) - [link](#)

JAMA Psychiatry

- Prenatal Antidepressant Exposure and Offspring Brain Morphologic Trajectory - [link](#)
- Efficacy and Safety of Antidepressants in Patients With Comorbid Depression and Medical Diseases: An Umbrella Systematic Review and Meta-Analysis – [link](#) – [SPS commentary](#)
- Association Between Stimulant Treatment and Substance Use Through Adolescence Into Early Adulthood - [link](#)
- Gabapentin Use Among Individuals Initiating Buprenorphine Treatment for Opioid Use Disorder - [link](#)

Journal of Clinical Oncology

- Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized Phase III ATALANTE/ENGOT-ov29 trial - [link](#)
- Survival of patients with cancer with DPYD variant alleles and dose-individualized fluoropyrimidine therapy—a matched-pair analysis - [link](#)
- Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994 - [link](#)
- Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer – [link](#) – [SPS commentary](#)
- Effect of metformin versus placebo on new primary cancers in Canadian Cancer Trials Group MA.32: a secondary analysis of a Phase III randomized double-blind trial in early breast cancer - [link](#)

Journal of Pharmacy Practice and Research (JPPR)

- Selecting performance indicators for hospital pharmacy practice: A Canadian initiative - [link](#)
- A retrospective study investigating the management, risk factors, and outcomes of patients diagnosed with *Clostridioides difficile* infection - [link](#)

Lancet

- Childhood nephrotic syndrome - [link](#)

- series on cystic fibrosis – [link](#) – [SPS commentary](#)

Lancet Diabetes & Endocrinology

- The optimal healthy ranges of thyroid function defined by the risk of cardiovascular disease and mortality: systematic review and individual participant data meta-analysis - [link](#)
- Current insights and emerging trends in early-onset type 2 diabetes - [link](#)

Lancet Gastroenterology and Hepatology

- Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial - [link](#)
- NASH (nonalcoholic steatohepatitis), drug treatment development: challenges and lessons - [link](#)

Lancet Haematology

- Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study - [link](#)

Lancet HIV

- Emergent HIV drug resistance in non-inferiority trials - [link](#)

Lancet Oncology

- Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial – [link](#) – [SPS commentary](#)

Lancet Respiratory Medicine

- Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis – [link](#) – [SPS commentary](#)
- Effect of once-per-day tacrolimus versus twice-per-day ciclosporin on 3-year incidence of chronic lung allograft dysfunction after lung transplantation in Scandinavia (ScanCLAD): a multicentre randomised controlled trial – [link](#) – [SPS commentary](#)

Medical Journal of Australia

- Activating pharmacists to reduce the frequency of medication-related problems (ACTMed): a stepped wedge cluster randomised trial - [link](#)
- Management of opiate dependence related to dihydrocodeine–sorbitol misuse - [link](#)

New England Journal of Medicine

- Phase 3 Trial of Concizumab in Hemophilia with Inhibitors – [link](#) – [SPS commentary](#)
- Current and Emerging Issues in Wilson’s Disease - [link](#)
- Antibiotic Prophylaxis in Infants with Grade III, IV, or V Vesicoureteral Reflux – [link](#) – [SPS commentary](#)

Organic Process Research & Development

- Formation of N-Nitrosamine Drug Substance Related Impurities in Medicines: A Regulatory Perspective on Risk Factors and Mitigation Strategies - [link](#)

Pharmacotherapy

- CYP2D6-guided opioid therapy for adults with cancer pain: a randomized implementation clinical trial - [link](#)
- Fluoroquinolone-Associated Adverse Events of Interest among Hospitalized Veterans Affairs Patients with Community-Acquired Pneumonia Who Were Treated with a Fluoroquinolone: A Focus on Tendonitis, Clostridioides difficile Infection, and Aortic Aneurysm - [link](#)
- Transitioning Disopyramide to Mavacamten in Obstructive Hypertrophic Cardiomyopathy: A Case Series and Clinical Guide - [link](#)

- Switching from intravenous vancomycin to oral antibiotics reduces adverse events in a retrospective cohort of outpatients with orthopedic infections - [link](#)

Prescribe – French Medical Journal

- Nivolumab (Opdivo^o) in advanced gastric or oesophageal cancer - [link](#)
- Dulaglutide, exenatide, liraglutide and other GLP-1 receptor agonists: thyroid cancer - [link](#)
- Glucarpidase (Voraxaze^o) for high-dose methotrexate toxicity - [link](#)
- Conditional marketing authorisation: easier to grant than to revoke - [link](#)
- Drugs to avoid in the name of better patient care - 2023 update - [link](#)

Thorax

- COVID-19-associated pulmonary aspergillosis in mechanically ventilated patients: a prospective, multicentre UK study - [link](#)
- Super-responders to anti-IL-5/anti-IL-5R are characterised by high sputum eosinophil counts at baseline - [link](#)
- Atopic and non-atopic effects of fish oil supplementation during pregnancy - [link](#)

CONSULTATIONS (new additions in bold)

TGA

- Proposed amendments to the Poisons Standard – ACMS, ACCS and Joint ACMS-ACCS meetings, November 2023, closes 29 September 2023 - [link](#)

WEBINARS & PODCASTS

Australian Prescriber Podcasts

- [Episode 146](#): Medicines and children

FDA Division of Drug Information is presenting a [series](#) of CE webinars

- FDA Drug Topics: Naltrexone Injection for Opioid Use Disorder - FDA's Efforts to Reduce Medication Errors - October 24, 2023 - [link](#)

MJA Podcasts

- [Episode 23](#): Lower urgency care in the emergency department

UPCOMING EVENTS

(New additions listed in TAGMail)

AHHA

- Value-Based Health Care (VBHC) Congress 2023, 26-27 October 2023, Brisbane - register [here](#)
- 15th Hospital in the Home Society Annual Scientific Meeting, 15-17 November 2023, Adelaide – register [here](#)

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- National Medicines Symposium 2023, 8 November 2023 10:00-16:30 (AEDT), virtual – register [here](#)

FIP

- 81st FIP World Congress of Pharmacy and Pharmaceutical Sciences, 24-28 September 2023, Brisbane – still time to register [here](#)

NHMRC Medicines Intelligence Centre of Research Excellence

- 2023 Annual Research Symposium, 1-2 November 2023, Surry Hills Sydney – free registration [here](#)

Institute for Safe Medication Practices (ISMP)

- Improving Medication Safety, Costs, and Patient Outcomes Symposia, Saturday 14 October 2023 12:00pm to 1:00pm, San Francisco - register [here](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

Society of Hospital Pharmacists (SHPA)

- Medicines Management 2023, 47th SHPA National Conference, 2-4 November 2023, Cairns – register [here](#) by 2 October for early bird

Sydney Children's Hospital Network SCHN & Children's Medical Research Institute

- Westmead Research and Innovation Conference, 21-22 September 2023, Westmead, Sydney –

[program](#) - [registration](#) – [abstract submission](#)

- Advanced therapeutics joint symposia, 29-30 November 2023, Westmead, Sydney – save the date and [get on the mailing list](#)

UNSW

- Cardiac, Vascular, and Metabolic Medicine Symposium, 13 October 2023 12:00-18:00, Garvan Institute, Darlinghurst - free registration [here](#)

World Pharmacists Day

- 25th September 2023